Work

A phase 2 study on efficacy, safety and intratumoral pharmacokinetics of oral selinexor (KPT-330) in patients with recurrent glioblastoma (GBM).

Year: 2016

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2016.34.15_suppl.2077

Authors: Morten Mau-Sørensen, Scott Randall Plotkin, Patrick Y. Wen, Andrew L. Kung, Ulrik Niels Lassen, Jean-Richard Saint-Martin, Greg Wright, Aleksander Chudnovsky, Joel Ellis, Sharon Friedlander, Bert van Eijk, Sharon Shacham, Michael G. Kauffman, Andrew B. Lassman

Institutions: Rigshospitalet, Massachusetts General Hospital, Dana-Farber Cancer Institute, Columbia University Irving Medical Center, Herbert Irving Comprehensive Cancer Center, Karyopharm Therapeutics (United States)

Language: English

Topic: Glioma Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2513075758

Cites:

Cited by: 9

Related to: 10